HIV Breakthrough at American Gene Technologies Gets Researchers Closer to the Cure
201.6 هزار بار بازدید -
3 سال پیش
-
BREAKING NEWS: FIRST PATIENT RECEIVES
BREAKING NEWS: FIRST PATIENT RECEIVES THERAPY FOR HIV CURE:
[CLICK HERE: https://bit.ly/2ToW3ub]
In May 2021, American Gene Technologies (AGT), a clinical-stage biotechnology company, announced the treatment of the first participant in its Phase I clinical trial to evaluate the safety of the cell and gene therapy product AGT103-T. Designated as the RePAIR trial (Restore Potent Antiviral Immune Responses, NCT04561258), participants are infused once with their own CD4 T cells that were enriched, for cells capable of reacting to HIV, and genetically modified to resist infection. This is a first-in-human study for AGT103-T. The primary endpoint is safety; testing related to secondary endpoints evaluates responses to treatment including changes in the immune response to HIV. This video explains AGT's research and HIV cure program strategy.
If you like this video, please subscribe to our channel: @americangenetechnologies
Also, please leave us a comment to let us know how you liked it as well as any additional subjects you’d like us to cover.
About AGT103-T
AGT103-T is a genetically modified cell product made from a person's own cells. AGT's approach is unique in that it focuses on repairing the key immune system damage caused by HIV. When HIV infection causes this specific damage, killing of T helper cells required for immunity to HIV, the infected person becomes unable to eliminate the virus and thus, becomes chronically infected. AGT's approach is designed to repair the T helper cell defect and provide durable virus control that is not compromised by HIV strains that vary in sequence or use alternate ways to enter and infect T cells. AGT's AGT103-T HIV therapeutic drug should work to remove infected cells from the body and decrease or eliminate the need for lifelong antiretroviral treatment.
About American Gene Technologies
American Gene Technologies (AGT) is a clinical-stage cell and gene therapy company focusing on treatments and cures for acquire or inherited diseases and cancer. Operating in Rockville, MD, AGT designs and develops, and tests novel genetic medicines using a gene-delivery platform that accelerates early-stage testing and enables rapid translation to the clinic. The company has an extensive patent portfolio covering gene therapies for HIV disease, Phenylketonuria (PKU), and solid tumor forms of epithelial cancer.
For more information on AGT's Phase 1 clinical trial, visit clinicaltrials.gov (Study Identifier: NCT04561258).
Visit our website: https://www.americangene.com
Subscribe to our newsletter: https://bit.ly/3ughPNR
Follow the company on social media---
Twitter:
Jeff - @jeffreygalvin - Twitter: jeffreygalvin
AGT - @americangene - Twitter: americangene
LinkedIn:
Jeff - LinkedIn: jeff-galvin-60258
AGT - LinkedIn: american-gene-technologies-international-inc
Facebook/Instagram:
Facebook - Facebook: amerigene
Instagram - Instagram: americangenetechnologies
[CLICK HERE: https://bit.ly/2ToW3ub]
In May 2021, American Gene Technologies (AGT), a clinical-stage biotechnology company, announced the treatment of the first participant in its Phase I clinical trial to evaluate the safety of the cell and gene therapy product AGT103-T. Designated as the RePAIR trial (Restore Potent Antiviral Immune Responses, NCT04561258), participants are infused once with their own CD4 T cells that were enriched, for cells capable of reacting to HIV, and genetically modified to resist infection. This is a first-in-human study for AGT103-T. The primary endpoint is safety; testing related to secondary endpoints evaluates responses to treatment including changes in the immune response to HIV. This video explains AGT's research and HIV cure program strategy.
If you like this video, please subscribe to our channel: @americangenetechnologies
Also, please leave us a comment to let us know how you liked it as well as any additional subjects you’d like us to cover.
About AGT103-T
AGT103-T is a genetically modified cell product made from a person's own cells. AGT's approach is unique in that it focuses on repairing the key immune system damage caused by HIV. When HIV infection causes this specific damage, killing of T helper cells required for immunity to HIV, the infected person becomes unable to eliminate the virus and thus, becomes chronically infected. AGT's approach is designed to repair the T helper cell defect and provide durable virus control that is not compromised by HIV strains that vary in sequence or use alternate ways to enter and infect T cells. AGT's AGT103-T HIV therapeutic drug should work to remove infected cells from the body and decrease or eliminate the need for lifelong antiretroviral treatment.
About American Gene Technologies
American Gene Technologies (AGT) is a clinical-stage cell and gene therapy company focusing on treatments and cures for acquire or inherited diseases and cancer. Operating in Rockville, MD, AGT designs and develops, and tests novel genetic medicines using a gene-delivery platform that accelerates early-stage testing and enables rapid translation to the clinic. The company has an extensive patent portfolio covering gene therapies for HIV disease, Phenylketonuria (PKU), and solid tumor forms of epithelial cancer.
For more information on AGT's Phase 1 clinical trial, visit clinicaltrials.gov (Study Identifier: NCT04561258).
Visit our website: https://www.americangene.com
Subscribe to our newsletter: https://bit.ly/3ughPNR
Follow the company on social media---
Twitter:
Jeff - @jeffreygalvin - Twitter: jeffreygalvin
AGT - @americangene - Twitter: americangene
LinkedIn:
Jeff - LinkedIn: jeff-galvin-60258
AGT - LinkedIn: american-gene-technologies-international-inc
Facebook/Instagram:
Facebook - Facebook: amerigene
Instagram - Instagram: americangenetechnologies
3 سال پیش
در تاریخ 1400/03/06 منتشر شده
است.
201,668
بـار بازدید شده